ABG Innovation Capital Partners III GP Ltd - Q2 2021 holdings

$29.9 Million is the total value of ABG Innovation Capital Partners III GP Ltd's 7 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 28.6% .

 Value Shares↓ Weighting
AVIR NewATEA PHARMACEUTICALS INC$27,186,0001,265,631
+100.0%
91.01%
GNCA  GENOCEA BIOSCIENCES INC$878,000
-13.6%
375,0000.0%2.94%
+489.0%
SYBX  SYNLOGIC INC$801,000
+8.7%
205,9060.0%2.68%
+640.9%
ARPO  AERPIO PHARMACEUTICALS INC$676,000
+31.0%
400,0000.0%2.26%
+790.9%
LUNG SellPULMONX CORP$199,000
-99.5%
4,521
-99.5%
0.67%
-96.4%
IDRA  IDERA PHARMACEUTICALS INC$68,000
-6.8%
56,2500.0%0.23%
+533.3%
 NABRIVA THERAPEUTICS PLC$62,000
-18.4%
45,8490.0%0.21%
+462.2%
ExitATEA PHARMACEUTICALS INC$0-2,639,178
-100.0%
-80.08%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

  • Fan Yu #1
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2021-08-16
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
SYNLOGIC INC12Q3 202333.8%
AADI BIOSCIENCES INC9Q3 202337.2%
IDERA PHARMACEUTICALS INC9Q4 20222.4%
GENOCEA BIOSCIENCES INC8Q3 202232.1%
NABRIVA THERAPEUTICS PLC7Q2 20222.3%
CASTLE BIOSCIENCES INC6Q3 202377.2%
PULMONX CORP5Q4 202133.9%
AERPIO PHARMACEUTICALS INC3Q2 20212.3%
ATEA PHARMACEUTICALS INC2Q2 202191.0%
ATEA PHARMACEUTICALS INC1Q1 202180.1%

View ABG Innovation Capital Partners III GP Ltd's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-14
13F-HR2023-05-15
13F-HR2023-02-14
13F-HR2022-11-14
13F-HR2022-08-15
13F-HR2022-05-16
13F-HR2022-02-14
13F-HR2021-11-15

View ABG Innovation Capital Partners III GP Ltd's complete filings history.

Compare quarters

Export ABG Innovation Capital Partners III GP Ltd's holdings